Colorectal cancer
An oncomicrobial vaccine targeting tumour-associated bacteria implicated in colorectal cancer (CRC).
RhogenShield develops self-adjuvanting therapies built on outer membrane vesicles (OMVs) — targeting the bacteria behind colorectal cancer, tuberculosis, drug-resistant ESKAPE infections, and chronic diabetic foot ulcers.
Outer membrane vesicles loaded with CRC-specific neoantigens and epitopes — the vaccine cargo at the heart of our colorectal cancer program.
Sound on — tap the speaker icon in the player to unmute.
Bacteria drive some of medicine's hardest problems — from the microbes implicated in colorectal cancer, to tuberculosis, to the drug-resistant ESKAPE pathogens behind chronic, non-healing wounds like diabetic foot ulcers. We're building self-adjuvanting, OMV-based vaccines and therapies to prevent and treat them.
Outer membrane vesicles (OMVs) are nanoscale particles naturally shed by bacteria. They present bacterial antigens alongside built-in immune-activating signals — a proven, self-adjuvanting route to vaccines and therapies against bacterial disease.
A cutaway of an OMV — an LPS-rich outer membrane studded with lipoproteins, enclosing periplasm-derived cargo such as enzymes, toxins and nucleic acids. This natural payload is exactly what our vaccines and therapies are engineered to harness.
OMVs carry natural immune-activating signals — strong responses without a separate adjuvant.
Reprogram against a new pathogen by swapping the antigens the OMVs display.
Engages antibody and T-cell responses — valuable against intracellular and resistant bacteria.
Grown by microbial fermentation — a route to high volumes at low cost for wider access.
We apply our OMV platform across four high-burden bacterial challenges where better prevention and treatment are urgently needed.
An oncomicrobial vaccine targeting tumour-associated bacteria implicated in colorectal cancer (CRC).
An antibacterial vaccine against Mycobacterium tuberculosis, one of the world's deadliest infections.
Vaccines against the ESKAPE panel of antibiotic-resistant bacteria driving antimicrobial resistance (AMR).
An engineered OMV therapy, delivered in a gel matrix, to fight the resistant infections that keep diabetic foot ulcers (DFU) from healing.
Specific tumour-associated bacteria are enriched in colorectal tumours, where they promote inflammation and cancer progression.
Our OMV-based oncomicrobial vaccine presents these bacteria-derived antigens to the immune system — activating T-cells that migrate to the tumour and attack the microbial environment that supports the cancer.
Diabetic foot ulcers are chronic, hard-to-heal wounds fuelled by drug-resistant bacteria and biofilms — a leading cause of amputation.
We're developing engineered OMVs delivered in an oleogel-based film — a gel matrix applied directly to the wound to target the underlying infection and support healing.
We're a small, ambitious team building vaccines against the world's toughest bacteria. If that excites you, we'd love to hear from you.
Lead the development of our tuberculosis (TB) vaccine — from antigen design through preclinical immunology and characterisation.
Whether you're an investor, researcher, manufacturer or public-health partner, we'd love to hear from you.